Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies, has appointed John F. McDonald to its Board.
John currently serves as Corporate Vice President, Global R&D Business Development, for Novo Nordisk A/S, where he leads R&D business development activities and investment strategies. From 2011 to 2018, John was Vice President, Business Development, at Biogen Inc. and prior to that role, served as Managing Director at MPM Capital LP. His earlier career included roles across business development, corporate strategy, and legal at various biopharmaceutical companies.
John holds a J.D. from University of California Hastings College of the Law and an M.B.A. and B.S. from the Haas School of Business, University of California, Berkeley.
Geron is a longstanding client for whom Occam had previously placed two independent Board members, Dawn Bir and Liz O’Farrell, and more recently, Chief Business Officer Edward Koval and VP Investor Relations & Corporate Communications Aron Feingold.